A transcriptional signature of Alzheimer’s disease is associated with a metastable subproteome at risk for aggregation

Prajwal Ciryam, Rishika Kundra, Rosie Freer, Richard I. Morimoto, Christopher M. Dobson, Michele VendruscoloProceedings of the National Academy of Sciences 2016 · DOI

TL;DR

This study reveals that Alzheimer's disease (AD) is characterized by a specific transcriptional signature: the down-regulation of genes encoding "metastable" proteins prone to aggregation. This suggests a coordinated cellular defense mechanism to mitigate protein aggregation when the cell's protein homeostasis machinery is compromised.

What Problem Does This Paper Address?

Alzheimer's disease (AD) is a devastating neurodegenerative condition marked by widespread changes in gene expression. However, it's been unclear whether these changes are a general sign of cellular breakdown or a specific, coordinated response to the disease's core pathology: protein misfolding and aggregation. The authors aim to untangle this by investigating the relationship between transcriptional changes, aging, and the inherent tendency of proteins to aggregate. Specifically, they question if the down-regulation of certain genes in AD is a deliberate strategy to reduce the risk of protein aggregation when cellular systems are under stress.

Methods

The researchers employed a meta-analysis approach, combining data from approximately 1,600 human central nervous system microarrays. This allowed them to systematically identify transcriptional changes associated with both normal aging and Alzheimer's disease. A key aspect of their strategy was to define and analyze "metastable" proteins – those that are supersaturated, meaning their concentration exceeds their solubility limit, making them inherently prone to aggregation. They then correlated these metastable proteins with genes that are transcriptionally down-regulated in AD. They also utilized pathway enrichment analysis (using KEGG database) to identify functional implications of these transcriptional changes.

Datasets

The study's primary data source was a meta-analysis of approximately 1,600 human central nervous system microarrays. These datasets were sourced from publicly available repositories, including Gene Expression Omnibus (GEO). The authors also referenced existing datasets for protein aggregation information (e.g., proteins co-aggregating with amyloid plaques and neurofibrillary tangles) and protein supersaturation data from previous work. A separate meta-analysis was conducted on microarrays from patients with clinical depression to serve as a control for disease-specific transcriptional responses.

Key Insights and Ideas

  • AD has a specific "metastable subproteome" signature: The study identifies a distinct set of genes that are both highly expressed and encode proteins prone to aggregation, and these genes are significantly down-regulated in AD. This suggests a targeted response rather than general cellular decline.
  • Down-regulation as a defense mechanism: The down-regulation of these metastable proteins appears to be a strategy to reduce the burden on compromised protein homeostasis mechanisms in AD, thereby mitigating aberrant protein aggregation.
  • Aging vs. AD: Distinct but related: While AD shares some transcriptional changes with aging, it's not simply an acceleration of the aging process. AD involves a more profound and distinct transcriptional response, with over three-quarters of AD-specific changes not occurring in aging.
  • Oxidative phosphorylation is a key target: The authors found that pathways related to oxidative phosphorylation are particularly enriched in metastable proteins and are significantly down-regulated in AD. This aligns with previous findings but provides a new mechanistic interpretation.
  • Metastability is a driver, not just a consequence: The research strongly suggests that the inherent metastability of proteins is a key factor driving the observed transcriptional changes in AD.

Key Results

  • A meta-analysis of ~1,600 microarrays identified a set of down-regulated genes in AD that encode proteins metastable to aggregation.
  • Proteins that co-aggregate with amyloid plaques and neurofibrillary tangles are disproportionately represented among genes down-regulated in AD and aging.
  • Proteins encoded by genes down-regulated in AD were found to be approximately 8.8-fold more metastable than those with unchanged expression.
  • Biochemical pathways enriched in metastable proteins (e.g., oxidative phosphorylation, Parkinson's disease, Huntington's disease) showed a strong correspondence with pathways down-regulated in AD.
  • The transcriptional response in AD is significantly different from that in clinical depression, suggesting the identified signature is specific to neurodegenerative proteinopathies.

Limitations and Future Work

The authors acknowledge that the aging component in their model was treated as a linear variable, and the assumption of linearity might hold best near the average age. They also note that while oxidative phosphorylation is a key pathway, the overall findings on protein metastability remain robust even when excluding proteins from this pathway.

Future work could focus on developing interventions that target this identified "metastable subproteome" for early diagnosis and treatment of AD. Further investigation into the specific transcriptional regulators that orchestrate this response could also yield valuable therapeutic targets. Understanding how endogenous strategies for handling supersaturated and metastable proteins can be modulated might pave the way for novel therapeutic approaches.

Summary updated

Abstract

It is well-established that widespread transcriptional changes accompany the onset and progression of Alzheimer's disease. Because of the multifactorial nature of this neurodegenerative disorder and its complex relationship with aging, however, it remains unclear whether such changes are the result of nonspecific dysregulation and multisystem failure or instead are part of a coordinated response to cellular dysfunction. To address this problem in a systematic manner, we performed a meta-analysis of about 1,600 microarrays from human central nervous system tissues to identify transcriptional changes upon aging and as a result of Alzheimer's disease. Our strategy to discover a transcriptional signature of Alzheimer's disease revealed a set of down-regulated genes that encode proteins metastable to aggregation. Using this approach, we identified a small number of biochemical pathways, notably oxidative phosphorylation, enriched in proteins vulnerable to aggregation in control brains and encoded by genes down-regulated in Alzheimer's disease. These results suggest that the down-regulation of a metastable subproteome may help mitigate aberrant protein aggregation when protein homeostasis becomes compromised in Alzheimer's disease.
BibTeX
@inproceedings{ciryam2016transcriptional,
  author = {Prajwal Ciryam and Rishika Kundra and Rosie Freer and Richard I. Morimoto and Christopher M. Dobson and Michele Vendruscolo},
  title = {{A transcriptional signature of Alzheimer’s disease is associated with a metastable subproteome at risk for aggregation}},
  booktitle = {Proceedings of the National Academy of Sciences},
  year = {2016},
  doi = {10.1073/pnas.1516604113},
}
Figure